Severe Food Allergies: Emergency Response and Long-Term Management

The Scope of Severe Food Allergies: Prevalence and Rising Incidence

Food allergies represent a significant and growing public health concern affecting children and adults worldwide, with reactions ranging from mild symptoms to life-threatening anaphylaxis triggered by common allergens such as milk, eggs, peanuts, and shellfish. 1 According to Food Allergy Research and Education (FARE), roughly 33 million Americans live with food allergies, and 13.7% of people in the United States Peanut and Tree Nut Allergy Registry have reported experiencing a reaction in a restaurant or food establishment. 2 The majority of allergic reactions are caused by nine common food sources: milk, soy, eggs, peanuts, fish, shellfish, wheat, tree nuts, and sesame. 3

The global incidence of anaphylaxis is on the rise, especially among children, though fatal outcomes remain uncommon. The estimated lifetime prevalence of anaphylaxis ranges from 0.3% to 5.1%, with regional variation in primary triggers: in Western countries, peanuts and tree nuts predominate; in East Asia, hen's eggs and cow's milk are most frequent; and in Southeast Asia, seafood is the leading cause. 4 Drug-induced anaphylaxis, often the main cause of anaphylaxis-related deaths worldwide, is increasing due to the growing use of chemotherapies and biologic agents, while insect stings cause approximately 10% of all cases. 4 In the United States, the American Academy of Allergy, Asthma and Immunology cites approximately 1,500 deaths annually attributable to anaphylaxis. 5

Recognizing Anaphylaxis: Clinical Criteria and Symptom Profiles

Anaphylaxis is defined by the World Allergy Organization as a serious, generalized, or systemic hypersensitivity reaction that is life-threatening because of involvement of the airway, breathing, or circulatory system. 5 It is a rapid-onset, potentially fatal systemic hypersensitivity reaction marked by airway, breathing, or circulatory compromise, which may occur even without skin symptoms, driven primarily by mast-cell activation through IgE-mediated pathways leading to the release of mediators such as tryptase and histamine. 6 The AAAAI 2023 practice parameter update notes that severe anaphylaxis is characterized by life-threatening respiratory and circulatory compromise, and it may occur without typical skin features or shock. 7

Symptoms can begin within minutes or several hours after exposure to an allergy trigger and span multiple organ systems. Documented presentations include shortness of breath, wheezing, tightness in the chest, swelling of the lips or tongue, weak pulse, vomiting, diarrhea, dizziness, and a feeling of impending doom. 8 In a six-year pediatric emergency department study, cutaneous symptoms appeared in 60.7% of cases and gastrointestinal symptoms such as vomiting in 41.0%, while hypotension was observed in 45% of the most severe Grade 4 reactions. 9 Infants may present differently, with irritability, inconsolable crying, sudden drooling, or unusual sleepiness as additional indicators. 8

Emergency Response: Epinephrine as the Cornerstone of Treatment

Immediate intramuscular epinephrine injected into the lateral thigh is the first-line treatment for anaphylaxis, with repeat dosing as needed. 6 Meeting diagnostic criteria for anaphylaxis is not required before the use of epinephrine, and neither the decision to administer it nor the response to it should be used as a surrogate marker to establish an anaphylaxis diagnosis. 7 A 34-member international panel of experts, publishing in the Journal of Allergy and Clinical Immunology in December 2025, reached consensus that epinephrine should be administered when multi-system symptoms involving two different body systems are present, or when any single severe symptom occurs. 10 These guidelines, led by Timothy Dribin, MD, of Cincinnati Children's, represent the first unified international recommendations clarifying when to administer epinephrine in community settings. 10

Despite epinephrine's critical role, its administration is frequently delayed or insufficiently used in real-world settings. 4 Barriers identified in the literature include needle aversion, device complexity, and access challenges, all of which contribute to suboptimal outcomes. 11 Adjunctive measures following epinephrine administration include oxygen, intravenous fluids, and bronchodilators for bronchospasm. Antihistamines and corticosteroids may alleviate some symptoms but do not reverse anaphylaxis and are no longer recommended for routine first-line management according to updated UK national guidance. 12 Clinicians are also advised to draw an acute-phase tryptase level as early as possible, ideally within two hours of symptom onset, and a second measurement later as a baseline to determine if a significant elevation occurred. 7

Biphasic and Refractory Anaphylaxis: Understanding Ongoing Risk

The AAAAI 2023 guideline update identifies two clinically significant complications of anaphylaxis that require extended vigilance. Biphasic anaphylaxis is highly likely when symptoms recur within 48 hours without allergen re-exposure, after initial signs have completely resolved for at least one hour. 7 This pattern underscores why emergency department observation following an anaphylactic event remains clinically important even when a patient appears to have recovered after epinephrine administration.

Refractory anaphylaxis is defined as highly likely when symptoms continue despite appropriate epinephrine dosing and symptom-directed medical management. 7 A nationally representative case series on fatal food anaphylaxis, published in Clinical and Experimental Allergy in 2025, found that most fatal cases occurred in private residences, public places, or schools rather than in healthcare settings, reinforcing the importance of community-level preparedness. 13 Pediatric risk factor analysis has identified male sex, age over six years, drug allergies, and rapid symptom onset as independent risk factors for severe anaphylaxis requiring heightened clinical attention. 14

Long-Term Management: Avoidance, Action Plans, and Emerging Therapies

The foundational strategy for long-term food allergy management remains strict allergen avoidance, supported by thorough label reading. The FDA Food Allergen Labeling and Consumer Protection Act (FALCPA) mandates that food labels identify the source of any major food allergen in plain language, providing a regulatory layer of consumer protection. 15 Every individual with a known severe food allergy is advised to maintain a physician-signed Anaphylaxis Action Plan that details specific symptoms and the step-by-step response sequence to follow during a reaction. The Asthma and Allergy Foundation of America released the first validated food allergy anaphylaxis action plan in August 2025, available in English, Spanish, and several other languages, developed with direct patient input. 16

Emerging therapeutic strategies are reshaping the long-term risk landscape. The FDA has approved two treatments beyond avoidance: Palforzia, an oral immunotherapy for peanut allergy in children, and omalizumab, a monoclonal antibody approved as an adjunct therapy for food allergies. 17 Research published in the Annals of Allergy Asthma and Immunology in 2025 documented improved outcomes, reduced emergency visits, and improved quality of life for food allergy patients on omalizumab monotherapy. 18 However, omalizumab and oral immunotherapy do not remove the need for emergency epinephrine, and both require ongoing medical supervision. 19

School, Community, and Institutional Preparedness Frameworks

A 2025 clinical report from the American Academy of Pediatrics, published in Pediatrics and authored by Scott H. Sicherer and colleagues, updated guidance on food allergy management in schools. The report notes that food allergy affects up to 10% of children and that anaphylaxis is estimated to occur in 1 in 15 schools per year. 20 Recommended institutional measures include prescribing self-administered epinephrine to individual patients, implementing stock epinephrine programs for general school use, and training school personnel on prevention, recognition, and management of allergic reactions. 20

In restaurant and food service settings, 360training guidance published in February 2026 notes that severe allergic reactions can happen within minutes, meaning food handlers must know how to recognize signs, respond immediately, and prevent exposures through proper allergen management protocols. 2 Anaphylaxis results in an estimated 45,000 to 50,000 emergency room visits in the United States each year, with food being the most common trigger, underscoring the breadth of the preparedness challenge across all community settings. 16 Intranasal epinephrine is also emerging as a needle-free delivery alternative that may reduce barriers in community settings, though current evidence is largely based on pharmacokinetic and pharmacodynamic studies with limited pediatric clinical data. 21

Sources

1. NCBI Bookshelf - StatPearls: Food Allergies (Sharon F. Daley, Claudia M. Lopez) - ncbi.nlm.nih.gov
2. 360training - How to Handle a Food Allergy Emergency in a Restaurant (February 2026) - 360training.com
3. StatPearls Point of Care - Food Allergies Treatment and Management - statpearls.uk
4. Balkan Medical Journal - Recent Insights into the Epidemiology and Management of Anaphylaxis (Sato et al., 2025) - doi.org/10.4274/balkanmedj.galenos.2025.2025-5-86
5. Emergency Medicine Authority - Anaphylaxis: Emergency Diagnosis and Treatment - emergencymedicineauthority.com
6. World Allergy Organization Journal - WAO White Book on Allergy 2026: Overview of Anaphylaxis (Cardona, 2026) - doi.org/10.1016/j.waojou.2026.101338
7. Medscape Reference - Anaphylaxis: AAAAI 2023 Guideline Summary - reference.medscape.com
8. HealthyChildren.org (AAP) - Anaphylaxis in Infants and Children: Responding to Severe Allergic Reactions - healthychildren.org
9. International Archives of Allergy and Immunology - Clinical Characteristics and Severity of Pediatric Anaphylaxis (WAO Criteria, 2026) - doi.org/10.1159/000552773
10. PR Newswire / Journal of Allergy and Clinical Immunology - International Consensus Report on Epinephrine and EMS Activation (Dribin et al., December 2025) - prnewswire.com
11. Journal of Pediatrics Clinical Practice - Recent Updates in the Management of Anaphylaxis: the Role of the Pediatrician (Spergel et al., 2026) - doi.org/10.1016/j.jpedcp.2026.200223
12. Allergy UK - Recognising, Managing, and Treating Severe Allergic Reactions - allergyuk.org
13. Clinical and Experimental Allergy - Prehospital Care in Fatal Food Anaphylaxis: A Nationally Representative Case Series (Coveney et al., 2025) - doi.org/10.1111/cea.70189
14. Frontiers in Pediatrics - Clinical Characteristics of Anaphylaxis and Risk Factors for Severe Reactions in Children (Wang et al., 2026) - doi.org/10.3389/fped.2026.1769228
15. U.S. Food and Drug Administration - Food Allergen Labeling and Consumer Protection Act (FALCPA) - fda.gov
16. Asthma and Allergy Foundation of America - New Food Allergy Emergency Care Plan Press Release (August 2025) - aafa.org
17. Food Frontiers - Emerging Frontiers in Food Allergy Treatment: Progress, Challenges, and Prospects (Zahid et al., 2025) - doi.org/10.1002/fft2.70130
18. Annals of Allergy Asthma and Immunology - Improved Outcomes, Emergency Visits, and Quality-of-Life for Patients with Food Allergy on Omalizumab Monotherapy (Kim et al., 2025) - doi.org/10.1016/j.anai.2025.08.247
19. European Journal of Pediatrics - Novelties in the Pragmatic Management of Anaphylaxis in Pediatric Age (2026) - doi.org/10.1007/s00431-026-07147-3
20. PEDIATRICS (AAP) - Management of Food Allergy in Schools: Clinical Report (Sicherer et al., 2025) - doi.org/10.1542/peds.2025-073168
21. Icahn School of Medicine at Mount Sinai / Scholars - Epinephrine and EMS Activation Recommendations During Acute Allergic Reactions: International Consensus Report (Dribin, Sampson et al.) - scholars.mssm.edu